Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
about
Adjuvant radiotherapy following radical prostatectomy for prostate cancerAdjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trialThe Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerRadiation Therapy after Radical Prostatectomy: Implications for CliniciansSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.Prognostic outlier genes for enhanced prostate cancer treatment.Emergency surgery in patients who have undergone recent radiotherapy is associated with increased complications and mortality: review of 536 patients.Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.Counseling patients about sexual health when considering post-prostatectomy radiation treatment.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Identification of men with the highest risk of early disease recurrence after radical prostatectomyWhat are the outcomes of radical prostatectomy for high-risk prostate cancer?Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.Positive surgical margins at radical prostatectomy predict prostate cancer specific mortalityPreoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.Saudi Oncology Society clinical management guidelines for prostate cancer.Radiotherapy after radical prostatectomy: treatment recommendations differ between urologists and radiation oncologists.A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomyEvolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer.Postoperative radiotherapy after radical prostatectomy: indications and open questionsThe need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technologyTissue biomarkers for prostate cancer radiation therapy.Overall rate, location, and predictive factors for positive surgical margins after robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer.Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus StatementIs lymphovascular invasion a powerful predictor for biochemical recurrence in pT3 N0 prostate cancer? Results from the K-CaP databaseUse of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.Impact of surgical margin status on prostate-cancer-specific mortality.Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy.Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer.High-risk prostate cancer: the role of radical prostatectomy for local therapy.Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
P2860
Q24234347-00DB178A-1C65-467B-90B4-278922DFA227Q24605205-71E8571D-ED70-4DDC-BD48-6925460AD02BQ26738703-95BDEF67-4A43-443D-A095-BCDF578C926FQ26744531-263D4B35-327C-435C-9B1E-C3BE38B82A8FQ26747782-AD61F0CB-0168-4021-AA0F-D7DBD3709A9DQ27022847-A9812135-FC93-463D-A476-C04144C9E61CQ27346788-B1EB8866-1610-4533-A408-7451C773D2CBQ30244674-B582A8E8-A5EB-4E35-9418-0750EFF9702FQ33398240-BC931293-5205-4E2F-9269-D1BA77305402Q33669456-7B14DD5B-5C2C-4AC8-AA36-10442BE0C168Q33710312-79B087B5-DC88-4302-94D9-0C8F8486B990Q33759725-44543433-8271-4093-ACC7-FF906ECC89BEQ33825388-0B577849-F1BF-4DCD-A146-B57FC1071AACQ33927594-F85CD204-1F7E-4009-82FA-3C1379A8C526Q33965472-8ADB3F81-CD1A-47A2-8889-3949B3691F08Q33990394-1E0EE798-10D3-4C56-8835-E408C416FADEQ34013761-3D650FD8-6D0A-4B77-8640-010F08449ED5Q34206798-B73F5E48-7BCB-4352-927B-1E0250ED5EFFQ34437308-942FD672-3FAB-46C0-8512-5CC77121006DQ34812281-EE5767E2-462E-45CC-B909-AE239D8BBC00Q34997355-177BCCD9-FC34-49DF-B5A3-1170E011459DQ35041485-867D5164-2914-4640-ABA1-C8115065B57BQ35322697-E4187E63-1F9D-4EA5-A13D-83A94FC2DC5BQ35605945-7348115C-9DE9-4A7C-993A-E3FC3D77452DQ35863963-4493C1D1-DC0C-46DF-86DD-3641090631A0Q35894629-4E097F6C-33B5-4B49-B170-90F63618D09BQ36108451-36F7666B-F868-4B52-9D4F-73EEDE73CBF9Q36141341-C6A9170B-D90B-409E-9753-EBC3DE266F7FQ36530193-EF2B6B25-C5E4-4D68-B9E0-64D6994E00BFQ36710328-DF3FB4F5-2D78-406E-9AA7-AE875F5F2645Q36870722-C2A9B6D2-F7CA-431D-BBEC-CF7A1E2D2177Q37342222-EFC31540-D1FE-4C21-87EA-7B7C00038424Q37421927-431CFF66-D4D0-4BC8-BC8D-63DEC9C706CAQ37427663-BDF6B0BD-FB92-4159-B94E-9AB4259E708CQ37546041-99C8E0E8-2C5A-4C42-AE5E-C28604475612Q37705424-080279AD-8749-43C6-B271-06168761EAC3Q37823204-FB36DF02-290E-434C-A877-A7061B8B710FQ37861198-25C7285B-E503-4B87-9982-33F6FA7C7271Q37889109-EA79B7B0-8780-482E-910A-06478E4DB3EAQ37944906-8E359D36-992C-44EA-9526-3CFC7EB78519
P2860
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Identification of patients wit ...... ive radiotherapy: EORTC 22911.
@en
type
label
Identification of patients wit ...... ive radiotherapy: EORTC 22911.
@en
prefLabel
Identification of patients wit ...... ive radiotherapy: EORTC 22911.
@en
P2093
P356
P1476
Identification of patients wit ...... ive radiotherapy: EORTC 22911.
@en
P2093
EORTC 22911
Fritz H Schröder
Hein Van Poppel
Jean-Francois Bosset
Karl H Kurth
Kris Vekemans
Laurence Collette
Luigi Da Pozzo
Michel Bolla
Paul Van Cangh
P304
P356
10.1200/JCO.2006.10.4067
P407
P577
2007-09-01T00:00:00Z